Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
Dare Bioscience, Inc. (DARE) filed this Current Report on Form 8-K on March 17, 2026, regarding events occurring on March 16, 2026. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
The filing reports the completion of a Regulation A offering. The company issued 43,050 Investor Units at an offering price of $5.00 per unit.
- Total Units Issued: 43,050
- Components per Unit: One share of Series A Convertible Preferred Stock and two warrants to purchase one share of common stock each.
- Total Preferred Shares Issued: 43,050
- Total Warrants Issued: 86,100 (covering up to 86,100 shares of common stock).
- Offering Capacity: The offering was for up to 4,854,000 units; the current closing represents a partial fulfillment of this capacity.
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the increase in the company's capital structure through the issuance of Series A Convertible Preferred Stock and associated warrants. This transaction was conducted pursuant to an offering statement on Form 1-A qualified by the SEC on January 5, 2026.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the equity issuance. The terms of conversion and exercise for the securities were previously detailed in an 8-K filed on January 29, 2026.
Key Facts for Investor Verification
- Verify the total capital raised from the 43,050 units issued at $5.00 per unit.
- Review the January 29, 2026 Form 8-K for specific conversion rates and exercise prices of the Series A Preferred Stock and Investor Warrants.
- Confirm the remaining capacity available under the qualified Form 1-A offering (up to 4,854,000 total units).
- Assess the dilution impact of the 86,100 warrants and potential conversion of the 43,050 preferred shares on existing common stockholders.